Other News

ABBOTT RECEIVES FDA APPROVAL FOR WORLD’S FIRST DUAL CHAMBER LEADLESS PACEMAKER

Abbott’s breakthrough technology enables the world’s first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA battery Leadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow […]

Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation

DUBLIN–(BUSINESS WIRE)–Medtronic is excited by the updated European Hypertension Society (ESH) guidelines that highlight the role of renal denervation (RDN) as part of the hypertension care pathway. The guidelines were announced at the ESH 32nd Annual Meeting and simultaneously published in the Journal of Hypertension. This marks a turning point for RDN […]

CMS Establishes HCPCS code for Ultromics EchoGo® Heart Failure, Accelerating Access to Precision HFpEF Detection

OXFORD, England, July 5, 2023 /PRNewswire/ — Ultromics, a leading health technology company advancing a novel approach for detecting heart failure and its phenotypes, announced today the assignment of a new outpatient code by the Centers for Medicare and Medicaid Services (CMS), for its flagship product, EchoGo® Heart Failure. CMS established a new […]

FUJIFILM Sonosite Introduces the All-Touchscreen Sonosite ST POCUS System, Designed and Engineered to Support Procedural Workflows

BOTHELL, Wash., July 03, 2023 (GLOBE NEWSWIRE) — FUJIFILM Sonosite, Inc. – The world leader in point-of-care ultrasound (POCUS) solutions has added to its leading portfolio of systems with the launch of the Sonosite ST. Designed with the busy proceduralist in mind, Sonosite ST offers a new 21-inch all-touchscreen interface, a large […]

BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency

SUNNYVALE, Calif. , July 05, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval for the […]

AtriCure to Announce Second Quarter 2023 Financial Results

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter 2023 financial results on Tuesday, July 25, 2023. AtriCure will host an audio webcast at 4:30 […]

FEops Receives FDA Clearance for Its AI-Based Anatomical Analysis Capabilities

Enabling a time-efficient workflow and better-informed clinical decision making for structural heart interventions GENT, Belgium–(BUSINESS WIRE)–FEops announced today its new release of FEops HEARTguide™, including an AI-based anatomical analysis of MSCT images for the pre-operative planning of structural heart interventions. With this introduction, physicians don’t need to do the measurements […]

Bioheart (02185.HK) announces clinical result for Iberis-HTN at CIT 2023

SHANGHAI, June 29, 2023 /PRNewswire/ — Bioheart (02185.HK), together with its holding subsidiary Angiocare announces the clinical result for Iberis-HTN at China Interventional Therapeutics 2023. Iberis-HTN is a prospective, multicenter, blinded, randomized controlled trial to evaluate the safety and efficacy of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System for the treatment […]

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2023, the compensation committee of the company’s board of directors granted four new […]

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has set a date of September 13, 2023 for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an […]